Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma; and Birinapant that is in phase II clinical trial for treating colorectal cancer. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; MIV-828, a candidate drug for treating blood cancer; MIV-711, which is in phase II clinical trial for treating osteoarthritis; and MIV-802, a nucleotide-based drug candidate for treating hepatitis C infections. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
CIKN/A
Phone46 8 54 68 31 00
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees36
Next Earnings DateN/A
OptionableNot Optionable
Medivir AB (publ) (OTCMKTS:MVRBF) Frequently Asked Questions
What is Medivir AB (publ)'s stock symbol?
Medivir AB (publ) trades on the OTCMKTS under the ticker symbol "MVRBF."
What is the consensus analysts' recommendation for Medivir AB (publ)?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medivir AB (publ) in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medivir AB (publ).
Has Medivir AB (publ) been receiving favorable news coverage?
Media coverage about MVRBF stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Medivir AB (publ) earned a news impact score of -4.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Medivir AB (publ).
Who are Medivir AB (publ)'s key executives?
Medivir AB (publ)'s management team includes the folowing people:
- Dr. Uli Hacksell, CEO, Pres & Director (Age 69)
- Ms. Lotta Ferm, Interim Chief Financial Officer (Age 53)
- Dr. Christina Herder, Exec. VP of Strategic Bus. Devel. (Age 58)
- Mr. Erik Björk, Exec. Officer (Age 43)
- Dr. Linda Basse, Chief Medical Officer (Age 63)
How do I buy shares of Medivir AB (publ)?
Shares of MVRBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Medivir AB (publ)'s stock price today?
One share of MVRBF stock can currently be purchased for approximately $1.54.
What is Medivir AB (publ)'s official website?
How can I contact Medivir AB (publ)?
The company can be reached via phone at 46 8 54 68 31 00.
MarketBeat Community Rating for Medivir AB (publ) (OTCMKTS MVRBF)
| Community Ranking: | | 3.0 out of 5 ( ) |
| Outperform Votes: | | 15 (Thanks for Voting!) |
| Underperform Votes: | | 10 (Thanks for Voting!) |
| Total Votes: | | 25 |
